Trial Profile
Prospective, double-blind, randomized, two-part, placebo-controlled, cross-over study investigating the effect of sugammadex on anti-Xa anticoagulant activity of enoxaparin and the activated partial thromboplastin time (APTT) of unfractionated heparin (UFH)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Dec 2015
Price :
$35
*
At a glance
- Drugs Sugammadex (Primary) ; Enoxaparin sodium; Heparin
- Indications Blood coagulation disorders
- Focus Pharmacodynamics; Pharmacokinetics
- 30 Dec 2015 New trial record